Top-Rated StocksTop-RatedNASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $26.23 +0.95 (+3.76%) Closing price 04:00 PM EasternExtended Trading$26.24 +0.00 (+0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CG Oncology Stock (NASDAQ:CGON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CG Oncology alerts:Sign Up Key Stats Today's Range$25.28▼$26.6050-Day Range$15.59▼$29.0552-Week Range$14.80▼$40.47Volume634,915 shsAverage Volume827,465 shsMarket Capitalization$2.00 billionP/E RatioN/ADividend YieldN/APrice Target$58.22Consensus RatingBuy Company OverviewCG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More… CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCGON MarketRank™: CG Oncology scored higher than 48% of companies evaluated by MarketBeat, and ranked 601st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CG Oncology is -17.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CG Oncology is -17.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about CG Oncology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.90% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in CG Oncology has recently increased by 3.03%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.90% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in CG Oncology has recently increased by 3.03%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment1.47 News SentimentCG Oncology has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CG Oncology this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,760.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of CG Oncology is held by insiders.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGON Stock News HeadlinesLeonard E. Post Sells 1,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) StockApril 30, 2025 | insidertrades.comMorgan Stanley Has Lowered Expectations for CG Oncology (NASDAQ:CGON) Stock PriceMay 21, 2025 | americanbankingnews.comShocking discovery could help you target payouts on weekends…Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...May 29, 2025 | WealthPress (Ad)CG Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 13, 2025 | globenewswire.comJP Morgan Initiates Coverage of CG Oncology (CGON) with Overweight RecommendationMay 3, 2025 | msn.comCG Oncology Stock Price, Quotes and Forecasts | NASDAQ:CGON | BenzingaApril 29, 2025 | benzinga.comWhy CG Oncology, Inc. (CGON) Surged on MondayApril 29, 2025 | msn.comBuy Rating for CG Oncology, Inc. Driven by Cretostimogene’s Potential in Bladder Cancer Treatment Amid BCG ShortageApril 29, 2025 | tipranks.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $28.68 on January 1st, 2025. Since then, CGON shares have decreased by 7.9% and is now trading at $26.4180. View the best growth stocks for 2025 here. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09. The business earned $0.05 million during the quarter, compared to the consensus estimate of $0.53 million. CG Oncology had a negative trailing twelve-month return on equity of 18.97% and a negative net margin of 10,642.98%. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. Who are CG Oncology's major shareholders? CG Oncology's top institutional shareholders include Vanguard Group Inc. (7.66%), Wellington Management Group LLP (2.79%), Alliancebernstein L.P. (2.47%) and Goldman Sachs Group Inc. (1.01%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings5/13/2025Today5/29/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$58.22 High Stock Price Target$75.00 Low Stock Price Target$23.00 Potential Upside/Downside+122.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.61 million Net Margins-10,642.98% Pretax Margin-10,642.98% Return on Equity-18.97% Return on Assets-15.36% Debt Debt-to-Equity RatioN/A Current Ratio35.32 Quick Ratio35.32 Sales & Book Value Annual Sales$662,000.00 Price / Sales3,008.12 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-13.47Miscellaneous Outstanding Shares76,225,000Free FloatN/AMarket Cap$1.99 billion OptionableOptionable Beta1.08 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CGON) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.